Winthrop Partners WNY LLC Makes New Investment in Johnson & Johnson $JNJ

Key Points

• Winthrop Partners WNY LLC opened a new position in Johnson & Johnson during the fourth quarter, buying 13,283 shares valued at about $2.75 million. The stake represents 1.5% of the firm’s portfolio.
• Johnson & Johnson continues to draw institutional interest and analyst support, with 69.55% of shares held by institutions and a Wall Street consensus rating of Moderate Buy. Several major firms recently raised price targets or reiterated bullish views.
• The company reported solid quarterly results, beating earnings and revenue estimates, while also raising its dividend to $1.34 per share. However, the stock has been soft recently, down about 3% over the past few months despite positive pipeline news such as encouraging Erleada trial results.

Winthrop Partners WNY LLC bought a new stake in Johnson & Johnson (NYSE:JNJ - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 13,283 shares of the company's stock, valued at approximately $2,749,000. Johnson & Johnson comprises 1.5% of Winthrop Partners WNY LLC's portfolio, making the stock its 25th largest position.

Several other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Blueline Advisors LLC acquired a new position in Johnson & Johnson during the 4th quarter worth about $25,000. Cresta Advisors Ltd. acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth about $26,000. DecisionPoint Financial LLC lifted its stake in Johnson & Johnson by 104.2% during the 4th quarter. DecisionPoint Financial LLC now owns 147 shares of the company's stock valued at $30,000 after acquiring an additional 75 shares in the last quarter. Bay Harbor Wealth Management LLC lifted its position in shares of Johnson & Johnson by 49.0% during the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company's stock worth $31,000 after buying an additional 49 shares in the last quarter. Finally, Family CFO Inc bought a new stake in Johnson & Johnson in the fourth quarter worth about $31,000. 69.55% of the stock is currently owned by institutional investors.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson’s prostate cancer drug Erleada showed encouraging clinical results, with Reuters-reported data indicating it cut the risk of cancer spread or death by 20% in a study setting. That kind of pipeline progress can support longer-term revenue growth. Article Title
• Positive Sentiment: The company continues to be highlighted as a strong dividend stock, with articles pointing to Johnson & Johnson’s long history of dividend increases and its appeal to income-focused investors seeking stability in a volatile market. Article Title
• Positive Sentiment: Johnson & Johnson announced plans to invest more than $1 billion in a Florida contact lens manufacturing facility, reinforcing confidence in future operating capacity and U.S. production investment. Article Title
• Neutral Sentiment: Several commentary pieces describe JNJ as a defensive name that may hold up better if markets weaken, but these articles are largely opinion-based and do not add new fundamental catalysts. Article Title
• Negative Sentiment: Shares have been soft over the past few months, with one note saying the stock is down about 3% in three months despite solid results and pipeline progress. That recent weakness may be weighing on sentiment even as investors debate whether the dip is attractive. Article Title

Insider Buying and Selling

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have commented on JNJ shares. Citigroup raised their target price on Johnson & Johnson from $274.00 to $285.00 and gave the stock a "buy" rating in a research note on Tuesday, April 7th. Stifel Nicolaus raised their price objective on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a research report on Wednesday, April 15th. Bank of America lifted their price objective on shares of Johnson & Johnson from $253.00 to $254.00 and gave the stock a "neutral" rating in a report on Wednesday, April 15th. TD Cowen began coverage on Johnson & Johnson in a research note on Wednesday, April 8th. They issued a "buy" rating and a $250.00 target price on the stock. Finally, The Goldman Sachs Group lifted their price target on Johnson & Johnson from $265.00 to $275.00 and gave the stock a "buy" rating in a research note on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $253.04.

Johnson & Johnson Stock Down 0.0%

Shares of Johnson & Johnson stock opened at $228.37 on Monday. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. Johnson & Johnson has a 52-week low of $149.04 and a 52-week high of $251.71. The company's 50 day moving average price is $230.61 and its 200-day moving average price is $228.25. The stock has a market capitalization of $549.73 billion, a price-to-earnings ratio of 26.40, a P/E/G ratio of 2.24 and a beta of 0.26.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last announced its quarterly earnings results on Tuesday, April 14th. The company reported $2.70 earnings per share for the quarter, beating the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to analysts' expectations of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The firm's revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Equities research analysts forecast that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were issued a dividend of $1.34 per share. The ex-dividend date was Tuesday, May 26th. This represents a $5.36 dividend on an annualized basis and a yield of 2.3%. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio (DPR) is presently 61.97%.

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.